Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease.

1 March, 2024

Brain. 2024 Mar 1;147(3):961-969. doi: 10.1093/brain/awad428.PMID: 38128551 Free PMC article.

Read the article

Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation.

Brain. 2024 Mar 1;147(3):949-960. doi: 10.1093/brain/awad317.PMID: 37721482 Free PMC article

Read the article

Highly Accurate Blood Test for Alzheimer’s Disease Comparable or Superior to Clinical CSF Tests.

21 February, 2024

Nat Med. 2024 Feb 21. doi: 10.1038/s41591-024-02869-z. Online ahead of print.PMID: 38382645

Read the article

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease.

17 February, 2024

Mol Neurodegener. 2024 Feb 17;19(1):19. doi: 10.1186/s13024-024-00707-x.PMID: 38365825 Free PMC article.

Read the article

Putaminal T1/T2-weighted ratio is increased in PSP compared to PD and healthy controls, a multi-cohort study.

13 February, 2024

Parkinsonism Relat Disord. 2024 Feb 13;121:106047. doi: 10.1016/j.parkreldis.2024.106047. Online ahead of print.PMID: 38368753 Free article.

Read the article

The Relationship between p-tau217, p-tau231, and p-tau205 in the Human Brain Is Affected by the Cellular Environment and Alzheimer’s Disease Pathology.

11 February, 2024

Cells. 2024 Feb 11;13(4):331. doi: 10.3390/cells13040331.PMID: 38391945 Free PMC article.

Read the article

Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.

Lancet Neurol. 2024 Feb;23(2):168-177. doi: 10.1016/S1474-4422(23)00414-3.PMID: 38267189 Free article.

Read the article

Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.

8 February, 2024

Alzheimers Res Ther. 2024 Feb 8;16(1):31. doi: 10.1186/s13195-024-01391-1.PMID: 38331843 Free PMC article.

Read the article

Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease.

Ann Neurol. 2024 Feb;95(2):274-287. doi: 10.1002/ana.26818. Epub 2023 Oct 25.PMID: 37837382

Read the article

Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.

7 February, 2024

Brain. 2024 Feb 7:awae032. doi: 10.1093/brain/awae032. Online ahead of print.PMID: 38325331

Read the article

Diffusion weighted magnetic resonance spectroscopy revealed neuronal specific microstructural alterations in Alzheimer’s disease.

1 February, 2024

Brain Commun. 2024 Feb 1;6(1):fcae026. doi: 10.1093/braincomms/fcae026. eCollection 2024.PMID: 38370447 Free PMC article.

Read the article

Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology.

7 January, 2024

Mol Neurodegener. 2024 Jan 7;19(1):2. doi: 10.1186/s13024-023-00689-2.PMID: 38185677 Free PMC article.

Read the article

The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer’s disease patients and AppNL-F/NL-F mice.

2 January, 2024

M.Alzheimers Res Ther. 2024 Jan 2;16(1):4. doi: 10.1186/s13195-023-01375-7.PMID: 38167557 Free PMC article.

Read the article

Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.

1 January, 2024

JAMA Neurol. 2024 Jan 1;81(1):69-78. doi: 10.1001/jamaneurol.2023.4596.PMID: 38048096

Read the article

Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors.

3 December, 2023

Brain Commun. 2023 Dec 3;5(6):fcad333. doi: 10.1093/braincomms/fcad333. eCollection 2023.PMID: 38107504 Free PMC article.

Read the article

The molecular genetic landscape of human brain size variation.

28 November, 2023

Cell Rep. 2023 Nov 28;42(11):113439. doi: 10.1016/j.celrep.2023.113439. Epub 2023 Nov 14.PMID: 37963017 Free article.

Read the article

Effects of Brain Pathologies on Spatiotemporal Gait Parameters in Patients with Mild Cognitive Impairment.

31 October, 2023

J Alzheimers Dis. 2023;96(1):161-171. doi: 10.3233/JAD-221303.PMID: 37742636 Free PMC article.

Read the article

The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.

27 October, 2023

Nat Commun. 2023 Oct 27;14(1):6750. doi: 10.1038/s41467-023-42305-3.PMID: 37891183 Free PMC article.

Read the article

DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease.

3 October, 2023

Nat Aging. 2023 Oct;3(10):1201-1209. doi: 10.1038/s43587-023-00478-y. Epub 2023 Sep 18.PMID: 37723208 Free PMC article.

Read the article

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology.

11 September, 2023

Nat Aging. 2022 Dec;2(12):1138-1144. doi: 10.1038/s43587-022-00310-z.

Read the article

Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.

Neurology. 2023 Jul 4;101(1):e30-e39. doi: 10.1212/WNL.0000000000207358.

Read the article

Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

Alzheimer’s Disease Neuroimaging Initiative. JAMA Neurol. 2023 Jun 1;80(6):614-623. doi: 10.1001/jamaneurol.2023.1067.

Read the article

Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer’s disease.

Alzheimers Dement. 2023 Apr 27. doi: 10.1002/alz.13103

Read the article

Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms.

JAMA Neurol. 2023 Jul 1;80(7):749-756. doi: 10.1001/jamaneurol.2023.1323.

Read the article

Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders.

Aust N Z J Psychiatry. 2023 Jul 21:48674231187312. doi: 10.1177/00048674231187312.

Read the article

Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.

Nat Immunol. 2023 Sep;24(9):1540-1551. doi: 10.1038/s41590-023-01588-w.

Read the article

Blood biomarkers for Alzheimer’s disease in clinical practice and trials.

11 August, 2023

Nat Aging. 2023 May;3(5):506-519. doi: 10.1038/s43587-023-00403-3

Read the article

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease.

12 June, 2023

Nat Aging. 2023 Apr;3(4):391-401. doi: 10.1038/s43587-023-00380-7.

Read the article

Age-related and amyloid-beta-independent tau deposition and its downstream effects.

Brain. 2023 Aug 1;146(8):3192-3205. doi: 10.1093/brain/awad135.

Read the article

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL-F/NL-F knock-in mouse model of Alzheimer’s disease.

Alzheimers Res Ther. 2023 Mar 25;15(1):64. doi: 10.1186/s13195-023-01196-8.

Read the article

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease.

Brain Commun. 2023 Jan 24;5(2):fcad015. doi: 10.1093/braincomms/fcad015. eCollection 2023.

Read the article

Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.

Neurology. 2023 Apr 25;100(17):e1812-e1824. doi: 10.1212/WNL.0000000000207113.

Read the article

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.

JAMA Neurol. 2023 Apr 1;80(4):360-369. doi: 10.1001/jamaneurol.2022.5272.

Read the article

Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer’s disease.

Alzheimers Dement (Amst). 2023 Jan 30;15(1):e12390. doi: 10.1002/dad2.12390.

Read the article

Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.

O. Alzheimers Dement. 2023 Jul;19(7):2994-3004. doi: 10.1002/alz.12897.

Read the article

Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study.

Alzheimers Dement. 2023 Jul;19(7):2943-2955. doi: 10.1002/alz.12907.

Read the article

Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.

Alzheimers Dement. 2023 Jun;19(6):2497-2507. doi: 10.1002/alz.12875.

Read the article

Novel insights regarding the measurement properties of the SCOPA-AUT.

BMC Neurol. 2022 Dec 13;22(1):478. doi: 10.1186/s12883-022-03008-2.

Read the article

[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes.

Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1371-1383. doi: 10.1007/s00259-022-06065-4.

Read the article

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum.

Mol Neurodegener. 2022 Dec 12;17(1):81. doi: 10.1186/s13024-022-00586-0.

Read the article

The genetic regulation of protein expression in cerebrospinal fluid.

EMBO Mol Med. 2023 Jan 11;15(1):e16359. doi: 10.15252/emmm.202216359.

Read the article

Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction are Altered in Parkinson’s Disease and Related Disorders.

Mov Disord. 2023 Feb;38(2):267-277. doi: 10.1002/mds.29287.

Read the article

Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy.

Parkinsonism Relat Disord. 2023 Jan;106:105226. doi: 10.1016/j.parkreldis.2022.11.018.

Read the article

Gray matter hypoperfusion is a late pathological event in the course of Alzheimer’s disease.

J Cereb Blood Flow Metab. 2023 Apr;43(4):565-580. doi: 10.1177/0271678X221141139.

Read the article

CSF ferritin in the clinicopathological progression of Alzheimer’s disease and associations with APOE and inflammation biomarkers.

J Neurol Neurosurg Psychiatry. 2023 Mar;94(3):211-219. doi: 10.1136/jnnp-2022-330052.

Read the article

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease.

Nat Commun. 2022 Nov 4;13(1):6635. doi: 10.1038/s41467-022-34129-4.

Read the article

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease.

Clin Chem Lab Med. 2022 Oct 24;61(2):234-244. doi: 10.1515/cclm-2022-0516.

Read the article

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy.

Alzheimers Res Ther. 2022 Oct 4;14(1):144. doi: 10.1186/s13195-022-01081-w.

Read the article

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease.

Alzheimers Res Ther. 2022 Sep 24;14(1):139. doi: 10.1186/s13195-022-01074-9.

Read the article

Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical performance.

Alzheimers Dement. 2023 Apr;19(4):1403-1414. doi: 10.1002/alz.12787.

Read the article

Clinical performance and robustness evaluation of plasma amyloid-β42/40prescreening.

Alzheimers Dement. 2023 Apr;19(4):1393-1402. doi: 10.1002/alz.12801.

Read the article

Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease.

Brain. 2023 Apr 19;146(4):1602-1614. doi: 10.1093/brain/awac343.

Read the article

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease.

Brain. 2023 Apr 19;146(4):1592-1601. doi: 10.1093/brain/awac333.

Read the article

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.

Brain. 2023 Apr 19;146(4):1580-1591. doi: 10.1093/brain/awac329.

Read the article

Anterior cingulate sulcation is associated with onset and survival in frontotemporal dementia.

medRxiv. 2023 Mar 31:2023.03.30.23287945. doi: 10.1101/2023.03.30.23287945.

Read the article

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios.

JAMA Neurol. 2023 May 1;80(5):516-522. doi: 10.1001/jamaneurol.2023.0199.

Read the article

Spatial Navigation and Its Association With Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia.

17 June, 2022

Neurology. 2022 Nov 8;99(19):e2081-e2091. doi: 10.1212/WNL.0000000000201106.

Read the article

Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading.

Nat Commun. 2022 Aug 20;13(1):4899. doi: 10.1038/s41467-022-32592-7.

Read the article

An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease.

Alzheimers Dement. 2023 Apr;19(4):1204-1215. doi: 10.1002/alz.12751.

Read the article

Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.

Neurology. 2022 Sep 13;99(11):e1142-e1153. doi: 10.1212/WNL.0000000000200817.

Read the article

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.

Acta Neuropathol Commun. 2022 Jun 22;10(1):90. doi: 10.1186/s40478-022-01388-7.

Read the article

Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE ϵ4 carriers.

Brain Commun. 2022 May 22;4(3):fcac135. doi: 10.1093/braincomms/fcac135.

Read the article

Test-retest variability of plasma biomarkers in Alzheimer’s disease and its effects on clinical prediction models.

Alzheimers Dement. 2022 Jun 14:10.1002/alz.12706. doi: 10.1002/alz.12706.

Read the article

β-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.

Neurology. 2022 May 31;99(5):e476-87. doi: 10.1212/WNL.0000000000200605.

Read the article

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217.

Alzheimers Res Ther. 2022 May 14;14(1):67. doi: 10.1186/s13195-022-01005-8.

Read the article

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients.

Alzheimers Res Ther. 2022 Mar 29;14(1):46. doi: 10.1186/s13195-022-00990-0.

Read the article

Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer’s Disease Pathology and Cognitive Decline.

Biol Psychiatry. 2022 Jan 31:S0006-3223(22)00053-1. doi: 10.1016/j.biopsych.2022.01.012.

Read the article

Midsagittal corpus callosal thickness and cognitive impairment in Parkinson’s disease.

Eur J Neurosci. 2022 Apr;55(7):1859-1872. doi: 10.1111/ejn.15640.

Read the article

Subtypes of Alzheimer’s disease: questions, controversy, and meaning.

Trends Neurosci. 2022 May;45(5):342-345. doi: 10.1016/j.tins.2022.02.001.

Read the article

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.

Neurology. 2022 Mar 15;98(11):e1137-e1150. doi: 10.1212/WNL.0000000000200040.

Read the article

The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.

Mov Disord. 2022 Feb 8. doi: 10.1002/mds.28958.

Read the article

Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer’s disease and frontotemporal disorders in clinical settings.

Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12549.

Read the article

Components of gait in people with and without mild cognitive impairment.

Gait Posture. 2022 Mar;93:83-89. doi: 10.1016/j.gaitpost.2022.01.012.

Read the article

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.

JAMA Neurol. 2022 Mar 1;79(3):228-243. doi: 10.1001/jamaneurol.2021.5216.

Read the article

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

JAMA Neurol. 2022 Feb 1;79(2):149-158. doi: 10.1001/jamaneurol.2021.4654.

Read the article

Blood-based biomarkers for Alzheimer’s disease.

EMBO Mol Med. 2022 Jan 11;14(1):e14408. doi: 10.15252/emmm.202114408.

Read the article

Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation.

Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6.

Read the article

Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes.

J Parkinsons Dis. 2022;12(2):571-584. doi: 10.3233/JPD-212866.

Read the article

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.

J Alzheimers Dis. 2022;85(1):31-45. doi: 10.3233/JAD-210525.

Read the article

Insights on Genetic and Environmental Factors in Parkinson’s Disease from a Regional Swedish Case-Control Cohort.

J Parkinsons Dis. 2022;12(1):153-171. doi: 10.3233/JPD-212818.

Read the article

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Alzheimers Dement. 2022 Feb;18(2):283-293. doi: 10.1002/alz.12395.

Read the article

Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis.

Pain Pract. 2022 Jan;22(1):66-82. doi: 10.1111/papr.13051.

Read the article

The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.

Alzheimers Dement. 2022 Jan;18(1):103-115. doi: 10.1002/alz.12371.

Read the article

Prenatal Gyrification Pattern Affects Age at Onset in Frontotemporal Dementia.

Santillo A.Cereb Cortex. 2022 Jan 17:bhab457. doi: 10.1093/cercor/bhab457.

Read the article

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.

Alzheimer’s Disease Neuroimaging Initiative.Neurology. 2022 Jan 12:10.1212/WNL.0000000000013299. doi: 10.1212/WNL.0000000000013299.

Read the article

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels.

Acta Neuropathol Commun. 2022 Jan 6;10(1):3. doi: 10.1186/s40478-021-01307-2.

Read the article

Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson’s disease.

30 June, 2021

Abstract This study seeks a better understanding of possible pathophysiological mechanisms associated with cognitive impairment and dementia in Parkinson’s disease using structural and functional MRI. We investigated resting-state functional connectivity of important subdivisions of the caudate nucleus, putamen and thalamus, and also how the morphology of these structures are impacted in the disorder. We found

Read the article

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

24 June, 2021

Abstract A combination of plasma phospho-tau (P-tau) and other accessible biomarkers might provide accurate prediction about the risk of developing Alzheimer’s disease (AD) dementia. We examined this in participants with subjective cognitive decline and mild cognitive impairment from the BioFINDER (n = 340) and Alzheimer’s Disease Neuroimaging Initiative (ADNI) (n = 543) studies. Plasma P-tau,

Read the article

Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline.

14 June, 2021

Neurology. 2021 Dec 22:10.1212/WNL.0000000000013228. doi: 10.1212/WNL.0000000000013228. PMID: 34937781

Read the article

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

JAMA Neurol. 2021 Dec 20:e214654. doi: 10.1001/jamaneurol.2021.4654..PMID: 34928318 Free PMC article.

Read the article

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.

Neurology. 2021 Dec 14:10.1212/WNL.0000000000013211. doi: 10.1212/WNL.0000000000013211..PMID: 34906975

Read the article

The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals.

ALFA study†, BioFINDER, ADNI.Alzheimers Dement. 2021 Dec 8. doi: 10.1002/alz.12487.

Read the article

Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group.

Read the article

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.

CONCORD-AD investigators.J Alzheimers Dis. 2022;85(1):31-45. doi: 10.3233/JAD-210525.

Read the article

The global Alzheimer’s Association round robin study on plasma amyloid β methods.

Alzheimers Dement (Amst). 2021 Oct 14;13(1):e12242. doi: 10.1002/dad2.12242. eCollection 2021.

Read the article

Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease.

Sci Rep. 2021 Oct 6;11(1):19853. doi: 10.1038/s41598-021-99310-z.

Read the article

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.

JAMA Neurol. 2021 Nov 1;78(11):1375-1382. doi: 10.1001/jamaneurol.2021.3180.

Read the article

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.

Neurology. 2021 Oct 26;97(17):e1681-e1694. doi: 10.1212/WNL.0000000000012727. Epub 2021 Sep 7.

Read the article

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.

Advancing Research and Treatment for Frontotemporal Lobar Degeneration investigators.Lancet Neurol. 2021 Sep;20(9):739-752. doi: 10.1016/S1474-4422(21)00214-3.

Read the article

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum.

Alzheimers Res Ther. 2021 Aug 13;13(1):138. doi: 10.1186/s13195-021-00876-7.

Read the article

Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience.

Eur Radiol. 2022 Feb;32(2):1127-1134. doi: 10.1007/s00330-021-08177-1. Epub 2021 Jul 30.

Read the article

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease.

Brain. 2021 Dec 16;144(11):3505-3516. doi: 10.1093/brain/awab223.

Read the article

Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers.

EMBO Mol Med. 2021 Aug 9;13(8):e14398. doi: 10.15252/emmm.202114398. Epub 2021 Jul 13.

Read the article

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.

JAMA Neurol. 2021 Aug 1;78(8):961-971. doi: 10.1001/jamaneurol.2021.1858.

Read the article

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12395.

Read the article

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.

Nat Commun. 2021 Jun 11;12(1):3555. doi: 10.1038/s41467-021-23746-0.

Read the article

A multicentre validation study of the diagnostic value of plasma neurofilament light.

Nat Commun. 2021 Jun 7;12(1):3400. doi: 10.1038/s41467-021-23620-z.

Read the article

Sex differences in off-target binding using tau positron emission tomography.

Neuroimage Clin. 2021;31:102708. doi: 10.1016/j.nicl.2021.102708. Epub 2021 May 29.

Read the article

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.

Brain. 2021 Oct 22;144(9):2826-2836. doi: 10.1093/brain/awab163.

Read the article

The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.

Alzheimer’s Disease Neuroimaging Initiative (ADNI)* and the Swedish BioFINDER study.Alzheimers Dement. 2021 Jun 1. doi: 10.1002/alz.12371. Online ahead of print.

Read the article

A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.

Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2295-2305. doi: 10.1007/s00259-021-05401-4. Epub 2021 May 27.

Read the article

Health utility in preclinical and prodromal Alzheimer’s disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.

Alzheimers Dement. 2021 Nov;17(11):1832-1842. doi: 10.1002/alz.12355. Epub 2021 May 13.

Read the article

Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.

EMBO Mol Med. 2021 Jun 7;13(6):e14022. doi: 10.15252/emmm.202114022. Epub 2021 May 5.PMID: 33949133 Free PMC article.

Read the article

Four distinct trajectories of tau deposition identified in Alzheimer’s disease.

Nat Med. 2021 May;27(5):871-881. doi: 10.1038/s41591-021-01309-6. Epub 2021 Apr 29.

Read the article

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias.

Alzheimers Res Ther. 2021 Feb 8;13(1):38. doi: 10.1186/s13195-020-00756-6.

Read the article

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia.

Nat Med. 2020 Mar;26(3):379-386

Read the article

Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid,
tau, and cognition.

Sci Rep. 2021
Jan 21;11(1):1965.

Read the article

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s
disease.

Alzheimers Dement. 2021 Jan 25. Online ahead of print.

Read the article

Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s
disease.

Transl Psychiatry.
2021 Jan 26;11(1):76.

Read the article

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for
synaptic biomarkers.

Acta Neuropathol Commun. 2021 Feb 1;9(1):19.

Read the article

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future
conversion to Alzheimer dementia in patients with mild cognitive impairment.

Alzheimers Res Ther. 2021 Mar 27;13(1):68.

Read the article

A multisite analysis of the concordance between visual image interpretation and
quantitative analysis of [18F]flutemetamol amyloid PET images.

Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2183-2199

Read the article

Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s
disease.

J Neurol Neurosurg Psychiatry. 2021 Apr 13:jnnp-2020-325497.

Read the article

Biomarker testing in MCI patients-deciding who to test.

Alzheimers Res Ther. 2021 Jan 7;13(1):14.

Read the article

Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.

Alzheimer’s Disease Neuroimaging Initiative (ADNI).Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2259-2271

Read the article

Early stages of tau pathology and its associations with functional connectivity, atrophy and memory.

30 April, 2021

Abstract In Alzheimer’s disease, postmortem studies have shown that the first cortical site where neurofibrillary tangles appear is the transentorhinal region, a subregion within the medial temporal lobe that largely overlaps with area 35, and the entorhinal cortex. Here we used tau-PET imaging to investigate the sequence of tau pathology progression within the human medial

Read the article

Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.

3 February, 2021

Abstract Objective: To investigate the relationship between enlarged perivascular spaces (EPVS) and measures of Alzheimer disease (AD), small vessel disease (SVD), cognition, vascular risk factors, and neuroinflammation, we tested associations between EPVS and different relevant neuroimaging, biochemical, and cognitive variables in 778 study participants. Methods: Four hundred ninety-nine cognitively unimpaired (CU) individuals, 240 patients with mild cognitive

Read the article

Pre-analytical protocol for measuring Alzheimer’s disease biomarkers in fresh CSF.

Abstract Introduction: We aimed to establish a standardized, routine-use pre-analytical protocol for measuring Alzheimer’s disease (AD) biomarkers in cerebrospinal fluid (CSF). Methods: The effect of pre-analytical factors (sample collection/handling/storage/transportation) on biomarker levels was assessed using freshly collected CSF. Tube type/sterilization was assessed using previously frozen samples. A low-bind false-bottom tube (FBT, Sarstedt) was used for all experiments,

Read the article

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.

Abstract Biomarkers have revolutionized scientific research on neurodegenerative diseases, in particular Alzheimer’s disease, transformed drug trial design, and are also increasingly improving patient management in clinical practice. A few key cerebrospinal fluid biomarkers have been robustly associated with neurodegenerative diseases. Several novel biomarkers are very promising, especially blood-based markers. However, many biomarker findings have had

Read the article

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease.

29 January, 2021

Abstract Plasma levels of tau phosphorylated at threonine-217 (p-tau217) is a candidate tool to monitor Alzheimer’s disease. We studied 150 cognitively unimpaired participants and 100 patients with mild cognitive impairment in the Swedish BioFINDER study. P-tau217 was measured repeatedly for up to 6 years (median three samples per person, median time from first to last

Read the article

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease.

Abstract It is currently unclear how amyloid-β and tau deposition are linked to changes in synaptic function and axonal structure over the course of Alzheimer’s disease. Here, we assessed these relationships by measuring presynaptic (synaptosomal-associated protein 25, SNAP25; growth-associated protein 43, GAP43), postsynaptic (neurogranin, NRGN) and axonal (neurofilament light chain) markers in the CSF of

Read the article

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.

Abstract The development of tau-PET allows paired helical filament tau pathology to be visualized in vivo. Increased knowledge about conditions affecting the rate of tau accumulation could guide the development of therapies halting the progression of Alzheimer’s disease. However, the factors modifying the rate of tau accumulation over time in Alzheimer’s disease are still largely

Read the article

Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load.

Abstract Objective: To evaluate a novel β-amyloid (Aβ)-PET-based quantitative measure (Aβ accumulation index ), including the assessment of its ability to discriminate between participants based on Aβ status using visual read, CSF Aβ42/Aβ40, and post-mortem neuritic plaque burden as standards of truth. Methods: One thousand one hundred twenty-one participants (with and without cognitive impairment) were scanned

Read the article

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

Abstract Importance: There is an urgent need for inexpensive and minimally invasive blood biomarkers for Alzheimer disease (AD) that could be used to detect early disease changes. Objective: To assess how early in the course of AD plasma levels of tau phosphorylated at threonine 217 (P-tau217) start to change compared with levels of established cerebrospinal fluid (CSF)

Read the article

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

28 July, 2020

Importance: There are limitations in current diagnostic testing approaches for Alzheimer disease (AD). Objective: To examine plasma tau phosphorylated at threonine 217 (P-tau217) as a diagnostic biomarker for AD. Design, Setting, and Participants: Three cross-sectional cohorts: an Arizona-based neuropathology cohort (cohort 1), including 34 participants with AD and 47 without AD (dates of enrollment, May 2007-January 2019); the

Read the article

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

24 July, 2020

Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer’s disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a total of 589 individuals, including cognitively unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neurodegenerative diseases. Plasma P-tau181 was increased

Read the article

Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease

Importance Better understanding is needed of the degree to which individuals tolerate Alzheimer disease (AD)–like pathological tau with respect to brain structure (brain resilience) and cognition (cognitive resilience). Objective To examine the demographic (age, sex, and educational level), genetic (APOE-ε4 status), and neuroimaging (white matter hyperintensities and cortical thickness) factors associated with interindividual differences in

Read the article

Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia

Objective To investigate whether midlife atherosclerosis is associated with different dementia subtypes and related underlying pathologies. Methods Participants comprised the cardiovascular cohort of the Swedish prospective population‐based Malmö Diet and Cancer Study (N = 6,103). Carotid plaques and intima media thickness (IMT) were measured at baseline (1991–1994). Dementia incidence until 2014 was obtained from national

Read the article

Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease

Introduction: Differential patterns of brain atrophy on structural magnetic resonance imaging (MRI) revealed four reproducible subtypes of Alzheimer’s disease (AD): (1) “typical”, (2) “limbic-predominant”, (3) “hippocampal-sparing”, and (4) “mild atrophy”. We examined the neurobiological characteristics and clinical progression of these atrophy-defined subtypes. Methods: The four subtypes were replicated using a clustering method on MRI data

Read the article

Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.

14 June, 2020

Neurology. 2021 Jan 12;96(2):e193-e202.

Read the article

Plasma Phospho-Tau Identifies Alzheimer’s Co-Pathology in Patients with Lewy Body Disease.

Mov Disord. 2021 Mar;36(3):767-771

Read the article

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias.

Neurology. 2020 Dec 1;95(22):e3026-e3035.

Read the article

Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease.

Sci Adv. 2020 Nov 27;6(48)

Read the article

Plasma NT1 Tau is a Specific and Early Marker of Alzheimer’s Disease.

Ann Neurol. 2020 Nov;88(5):878-892.

Read the article

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease.

Neurobiol Aging. 2020 Nov;95:143-153.

Read the article

The impact of demographic, clinical, genetic, and imaging variables on tau PET status.

Eur J Nucl Med Mol Imaging. 2020 Nov 19.2021 Jul;48(7):2245-2258

Read the article

Acute phase markers in CSF reveal inflammatory changes in Alzheimer’s disease that intersect with pathology, APOE ε4, sex and age.

Prog Neurobiol. 2020 Aug 31:101904.

Read the article

Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases.

Neuroimage Clin. 2020;28:102386.

Read the article

Validation of a spatial normalization method using a principal component derived adaptive template for [18F]florbetaben PET.

Am J Nucl Med Mol Imaging. 2020 Aug 25;10(4):161-167. eCollection 2020.

Read the article

Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up.

Neuroimage Clin. 2020 Jun 10;27:102310.

Read the article

The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people.

J Gerontol A Biol Sci Med Sci. 2020 Jun 7:glaa143.

Read the article

Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease.

Nat Commun. 2020 May 26;11(1):2612.

Read the article

Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults.

Neurobiol Aging. 2020 Sep;93:1-15.

Read the article

CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers.

Sci Rep. 2020 May 19;10(1):8233.

Read the article

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

Sci Adv. 2020 Apr 15;6(16):eaaz2387.

Read the article

The implications of different approaches to define AT(N) in Alzheimer disease.

Neurology. 2020 May 26;94(21):e2233-e2244

Read the article

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.

JAMA Neurol. 2020 May 11:e200989.

Read the article

Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.

Lancet Neurol. 2020 May;19(5):422-433.

Read the article

Relationship between cortical iron and tau aggregation in Alzheimer’s disease.

Brain. 2020 May 1;143(5):1341-1349.

Read the article

Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease.

Brain. 2020 Apr 1;143(4):1233-1248.

Read the article

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease.

Nat Commun. 2020 Apr 3;11(1):1683.

Read the article

The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment.

Alzheimers Res Ther. 2020 Mar 24;12(1):30.

Read the article

Towards unconstrained compartment modeling in white matter using diffusion-relaxation MRI with tensor-valued diffusion encoding.

Reson Med. 2020 Sep;84(3):1605-1623.

Read the article

Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson’s disease.

Neurobiol Dis. 2020 Mar 4, 2020-06-01, Volume 139, Article 104831

Read the article

[18F]Flortaucipir Distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case.

Acta Neuropathol 2020 Feb;139(2):411-413.

Read the article

Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. 

Neurobiol Dis. 2020 Feb;134:104645.

Read the article

Head-to-head comparison of tau positron emission tomography tracers  [18F]flortaucipir and [18F]RO948.

Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):342-354.

Read the article

Apathy and anxiety are early markers of Alzheimer’s disease.

Neurobiol Aging. 2020 Jan;85:74-82.

Read the article

Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease.

Alzheimer’s Disease Neuroimaging Initiative (ADNI). Nat Commun. 2020 Jan 17;11(1):347.

Read the article

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume.

13 June, 2019

Alzheimers Res Ther. 2019 Dec 26;11(1):109.

Read the article

Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.

Mov Disord. 2020 Mar;35(3):513-518.

Read the article

Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies. 

Radiology. 2019 Dec;293(3):646-653.

Read the article

Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity.

Elife. 2019 Dec 9;8:e50830.

Read the article

Predicting Clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays

Sci Rep. 2019 Dec 13;9(1):19024.

Read the article

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease.

EMBO Mol Med. 2019 Dec;11(12):e11170.

Read the article

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease. 

Acta Neuropathol Commun. 2019 Nov 6;7(1):169.

Read the article

A quick test of cognitive speed can predict development of dementia in Parkinson’s disease. 

Sci Rep. 2019 Oct 28;9(1):15417.

Read the article

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid.

Commun Biol. 2019 Oct 8;2:365.

Read the article

Alzheimer’s Disease Neuroimaging Initiative. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.

Lancet Neurol. 2019 Nov;18(11):1034-1044

Read the article

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease. 

Alzheimers Res Ther. 2019 Sep 14;11(1):82

Read the article

Increased functional connectivity of thalamic subdivisions in patients with Parkinson’s disease.

PLoS One. 2019 Sep 4;14(9):e0222002.

Read the article

β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. 

Sci Rep. 2019 Aug 1;9(1):11180.

Read the article

α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson’s disease patients.  

Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15226-15235.

Read the article

Determining clinically meaningful decline in preclinical Alzheimer disease.

Neurology. 2019 Jul 23;93(4):e322-e333.

Read the article

Towards a unified protocol for handling of CSF before β-amyloid measurements. 

Alzheimers Res Ther. 2019 Jul 19;11(1):63.

Read the article

Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. 

JAMA Neurol. 2019 Jul 17;76(11)

Read the article

Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study.

Parkinsonism Relat Disord. 2019 Sep 6.

Read the article

European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND). 

Alzheimers Dement (Amst). 2019 Jul 31;11:538-549.

Read the article

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. 

JAMA Neurol. 2019 Sep; 76(9): 1060–1069

Read the article

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease. 

PLoS One. 2019 Jun 17;14(6):e0218561.

Read the article

Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. 

Sci Rep. 2019 Apr 15;9(1):6079.

Read the article

Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. 

Cereb Cortex. 2019 May 1;29(5):2173-2182

Read the article

Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling. 

Hum Brain Mapp. 2019 Jun 1;40(8):2529-2545.

Read the article

Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline.

Neuroradiology. 2019 Apr;61(4):397-404.

Read the article

Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer’s Disease. 

J Alzheimers Dis. 2019;69(4):1213-1220

Read the article

CSF placental growth factor – a novel candidate biomarker of frontotemporal dementia. 

Ann Clin Transl Neurol. 2019 Mar 29;6(5):863-872.

Read the article

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer’s disease: Cross-validation study of practical algorithms. 

Alzheimers Dement. 2019 Feb;15(2):194-204.

Read the article

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. 

Sci Rep. 2019 Feb 21;9(1):2460.

Read the article

Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease.

Hum Brain Mapp. 2019 Feb 1;40(2):638-651.

Read the article

Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer’s disease. 

Alzheimers Dement. 2019 Apr;15(4):570-580.

Read the article